Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.75 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL16635 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL226032 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL3531521 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL21907 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL21294081 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL1938248 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL8523755 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL10582956 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL22499922 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 | |
| Sulfuric Acid SCHEMBL20808 | 1.00 | CA5A (0.75) | CA5ACA5BTSHRCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974043-A | Production method of battery-grade nano sodium ferrous sulfate | 河北惠尔信新材料股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-114941135-A | Application of economic and environment-friendly chemical nickel plating stabilizer | 金川集团镍盐有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-108094207-B | Method for somatic embryogenesis and plant regeneration of slash pine | 广东省林业科学研究院 | 2020-01-31 | — | — | CN | claimed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | Kuleon, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | Kuleon, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | Kuleon, LLC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | Kuleon, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| EP-0859610-A4 | IBOGAMINE CONGENERS | ALBANY MEDICAL COLLEGE (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6211360-B1 | DRUG ABRUSE THERAPY; PLANT EXTRACTS | ALBANY MEDICAL COLLEGE | 2001-04-03 | — | — | US | disclosed |
| EP-0859610-A1 | IBOGAMINE CONGENERS | ALBANY MEDICAL COLLEGE (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997005869-A1 | IBOGAMINE CONGENERS | ALBANY MEDICAL COLLEGE (US) | 1997-02-20 | — | — | WO | disclosed |
| US-4513053-A | Encapsulated phase change thermal energy storage materials and process | PENNWALT CORPORATION (US) | 1985-04-23 | — | — | US | disclosed |
| US-4505953-A | COATING COMPACTED POWDER WITH LIQUID, AND CURING | PENNWALT CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| US-4504402-A | Encapsulated phase change thermal energy _storage materials | PENNWALT CORPORATION (US) | 1985-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | CA5A 1957/4885CA5B 2013/4885TSHR 186/4885 |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | CA5A 4283/4885CA5B 4320/4885TSHR 397/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | CA5A 4283/4885CA5B 4320/4885TSHR 397/4885 |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | CA5A 4732/4885CA5B 4659/4885TSHR 814/4885 |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | HTR2C, HTR2A, HTR3B | CA5A 4523/4885CA5B 4506/4885TSHR 334/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | CA5A 4586/4885CA5B 4506/4885TSHR 786/4885 |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | CA5A 4015/4885CA5B 3295/4885TSHR 3528/4885 |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | HTR2A, HTR2C, HTR3A | CA5A 3763/4885CA5B 3553/4885TSHR 457/4885 |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | HTR2A, HTR2C, HTR3A | CA5A 3763/4885CA5B 3553/4885TSHR 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.